Impact Biomedical Inc. cash flow statement

In fiscal 2025, Impact Biomedical Inc.'s operations generated −$1.9m of cash.

Cash flow statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Impact Biomedical Inc.: cash flow statement, annual
Fiscal year	2022Dec 2022	2025Dec 2025	LTMJun 2026
Cash from operations	−2,242	−1,890	−508
Depreciation and amortisation	1,113	1,145	1,143
Stock-based pay	—	13	1,449

US$ thousands unless shown otherwise. Fiscal quarters.

Impact Biomedical Inc.: cash flow statement, quarterly
Quarter	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Cash from operations	—	−802	−363	−694	−613	99	−464	470
Depreciation and amortisation	278	279	278	288	288	286	285	284
Stock-based pay	—	—	—	2	1	8	1,440	0

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: IBO vs LYEL AIM vs IBO IBIO vs IBO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Impact Biomedical Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Impact Biomedical Inc.